First Hawaiian Bank Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• First Hawaiian Bank increased its stake in Regeneron Pharmaceuticals by 21.5%, bringing its total shares to 3,639 valued at approximately $2.3 million.
• Recent analysis by various firms predicts a positive outlook for Regeneron, with price targets raised to as high as $831 and a consensus rating of "Moderate Buy".
• Regeneron Pharmaceuticals reported $12.89 earnings per share for its last quarter, exceeding expectations and illustrating a 3.6% year-over-year revenue growth.

First Hawaiian Bank lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,639 shares of the biopharmaceutical company's stock after purchasing an additional 644 shares during the period. First Hawaiian Bank's holdings in Regeneron Pharmaceuticals were worth $2,308,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $27,000. Finally, Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on REGN shares. Jefferies Financial Group boosted their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Morgan Stanley reiterated an "overweight" rating and set a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Finally, Citigroup reiterated a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Trading Down 1.4%

NASDAQ REGN opened at $560.00 on Friday. The company has a fifty day simple moving average of $564.61 and a two-hundred day simple moving average of $579.66. The stock has a market cap of $59.35 billion, a P/E ratio of 14.11, a P/E/G ratio of 1.90 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,170.58. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company posted $11.56 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.